A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs AST 008 (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Exicure
- 26 Dec 2018 Status changed from not yet recruiting to recruiting.
- 25 Sep 2018 Status changed from planning to not yet recruiting.
- 20 Sep 2018 According to an Exicure media release, the company expects to initiate this trial before year end and anticipates preliminary data from the Phase 1b stage in late 2019.